Peania 20 March, 2003 - Pioneer in the Research and Development of innovative technologies, Lavipharm Group announced the completion of the first application of its Solid Gel Technology, a new technology developed for the delivery of an active agent to the skin.

More specifically, the Solid Gel Technology creates thin films that contain active components, which with the use of solvents (water or serum, depending on the case) and with simultaneous inunction create a gel on the epidermis transporting the drastic substances on the skin safely and successfully.

The technology's solid form helps in the stabilization of sensitive substances and in the precise definition of dosages when needed. The film is very small in size and easy to use, has no side effects, doesn't cause any negative effects on the skin while at the same time protects the skin from external factors. It does not contain preservatives and its use doesn't prevent the skin's perspiration.

The important advantage of Solid Gel Technology is that it guarantees, with the easiest and friendliest way, the transmission of drastic components to the human epidermis. It may be applied both in Cosmetology (for the maintenance and intensive care of the skin) and in Pharmaceutics.

The first application of the Solid Gel technology has already circulated in the market as Lavipharm Group has recently completed the first skin care line, ?Clarte Extreme?, on behalf of Yves Saint Laurent. The line, which includes skin brightening products suitable for any skin type, has already been launched in the Japanese market while other countries will follow.

«Our strategic decision to focus on such a specialized areas of Pharmaceutical Research differentiates us from the competition and gives us a competitive advantage. This is recognized by well known multinationals that entrust us by choosing Lavipharm as their partner?, stated Dr. Athanase Lavidas, Chairman and CEO of Lavipharm Group. ?Having as our main goal the fundamental contribution to the future of human health, we are looking ahead envisioning the progress of pharmaceutical technology», continued Dr. Lavidas. Solid Gel Technology is the fourth drug delivery systems technology that Lavipharm applies, for which a patent application has already been submitted. The nitroglycerine patch for the angina was the first technology applied initially in 1995, which then circulated in many countries under the name of well known multinationals. In 1996 followed the first application of Lavipharm's epidermal technology, the patch for acne and imperfections of young skin by L'Oreal and GlaxoSmithKline. The Liquid patch technology has already been applied on products for the rejuvenation and care of the skin, where gel is transformed into a thin film.

Lavipharm is the largest integrated Group of companies in the development, production, import, promotion and distribution of pharmaceutical, dermocosmetic and consumer health products in Greece with a strong international activity. In 2002 Lavipharm's consolidated turnover exceeded euro 300 million.